Clinical Trial Update: Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients [NA]

View source ↗

Summary

A completed clinical trial assessing the impact of dapagliflozin on intestinal microbiota composition and microbiota-derived metabolites in non-diabetic chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Chronic Kidney Diseases | NA | Status: COMPLETED